Single Strain

DDS-1

JUMP TO:
01
Summary

In one clinical trial, Lactobacillus acidophilus DDS-1, provided at a dose of 10 billion CFU/day over 42 days, has demonstrated benefits in patients with IBS of unknown subtypes.1 DDS-1 significantly improved IBS symptom severity for: abdominal pain, abdominal pain duration, abdominal distention, bowel habits, effects on quality of life, and perceived stress. However, DDS-1 did not seem to have a significant impact on stool frequency. 

By day 42 of the trial, 84% of participants in the DDS-1 group experienced a normal stool form (bristol stool form of 3-5) compared to only 59% at baseline. This was accompanied by a decrease in the number of participants experiencing constipation and diarrhea. Direct comparisons of individual stool forms against the placebo group were not conducted between or within groups.Therefore, all improvements in stool consistency and form have been classified as improvements in bowel habits. Still, it’s important to recognize the potential of this probiotic for improving symptoms associated with constipation and diarrhea.

Key Takeaway

Lactobacillus acidophilus DDS-1 may be a reasonable probiotic choice for people with IBS who are seeking global symptom reduction, reduction in abdominal pain and distention, and improvements in bowel habits related to stool consistency but not frequency. 

 

Effective Dose(s) 10 billion CFU per day 
Form One capsule per day taken before a meal with water
Suggested Minimum Trial Duration  6 weeks 

 

 

References:

  1. Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020; 12(2):363. https://doi.org/10.3390/nu12020363

 

 

Read More…

In one clinical trial, Lactobacillus acidophilus DDS-1, provided at a dose of 10 billion CFU/day over 42 days, has demonstrated benefits in patients with IBS of unknown subtypes.1 DDS-1 significantly improved IBS symptom severity for: abdominal pain, abdominal pain duration, abdominal distention, bowel habits, effects on quality of life, and perceived stress. However, DDS-1 did not seem to have a significant impact on stool frequency. 

By day 42 of the trial, 84% of participants in the DDS-1 group experienced a normal stool form (bristol stool form of 3-5) compared to only 59% at baseline. This was accompanied by a decrease in the number of participants experiencing constipation and diarrhea. Direct comparisons of individual stool forms against the placebo group were not conducted between or within groups.Therefore, all improvements in stool consistency and form have been classified as improvements in bowel habits. Still, it’s important to recognize the potential of this probiotic for improving symptoms associated with constipation and diarrhea.

Key Takeaway

Lactobacillus acidophilus DDS-1 may be a reasonable probiotic choice for people with IBS who are seeking global symptom reduction, reduction in abdominal pain and distention, and improvements in bowel habits related to stool consistency but not frequency. 

 

Effective Dose(s) 10 billion CFU per day 
Form One capsule per day taken before a meal with water
Suggested Minimum Trial Duration  6 weeks 

 

 

References:

  1. Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020; 12(2):363. https://doi.org/10.3390/nu12020363

 

 

Read More…
Find a probiotic with DDS-1

Evaluate products based on whether they transparently disclose all ingredients and their amounts, exclusively use probiotics tested in randomized placebo-controlled trials in IBS populations, and contain studied doses.

View products containing this strain >

In one clinical trial, Lactobacillus acidophilus DDS-1, provided at a dose of 10 billion CFU/day over 42 days, has demonstrated benefits in patients with IBS of unknown subtypes.1 DDS-1 significantly improved IBS symptom severity for: abdominal pain, abdominal pain duration, abdominal distention, bowel habits, effects on quality of life, and perceived stress. However, DDS-1 did not seem to have a significant impact on stool frequency. 

By day 42 of the trial, 84% of participants in the DDS-1 group experienced a normal stool form (bristol stool form of 3-5) compared to only 59% at baseline. This was accompanied by a decrease in the number of participants experiencing constipation and diarrhea. Direct comparisons of individual stool forms against the placebo group were not conducted between or within groups.Therefore, all improvements in stool consistency and form have been classified as improvements in bowel habits. Still, it’s important to recognize the potential of this probiotic for improving symptoms associated with constipation and diarrhea.

Key Takeaway

Lactobacillus acidophilus DDS-1 may be a reasonable probiotic choice for people with IBS who are seeking global symptom reduction, reduction in abdominal pain and distention, and improvements in bowel habits related to stool consistency but not frequency. 

 

Effective Dose(s) 10 billion CFU per day 
Form One capsule per day taken before a meal with water
Suggested Minimum Trial Duration  6 weeks 

 

 

References:

  1. Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020; 12(2):363. https://doi.org/10.3390/nu12020363

 

 

02
Results
Overall evidence quality grade
90%

This probiotic has higher quality studies in IBS populations supporting it. View our evidence evaluation framework to learn how we assess the quality of studies.

Refine by Probiotic(s) In this view, show results

Close
  • Where trash
    trash

Add condition

03
Patient Handout
Share
Download
04
Clinical Studies
  • #
  • Study
  • Year
  • Author(s)
  • Journal
  • Reference
  • Daily Dose
  • Duration of Intervention
  • Form
  • Study Design
  • Age
  • Participants
    • Study #1

    • Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UAB1a-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial

    • 2020
    • Martoni CJ, Srivastava S, Leyer GJ.

    • Nutrients 2020;12:363

    • DOI: 10.3390/nu12020363
    • 10 billion CFU
    • 6 weeks
    • Capsule
      • RANDOMIZED
      • DOUBLE-BLIND
      • PLACEBO-CONTROLLED
      • MULTICENTER
      • PROSPECTIVE
      • PARALLEL-ARM

    • ADULTS     18-70 years

    • ITT,PP (total) n=336,318
      ITT,PP (UABIa-12 ) n=111,105
      ITT,PP (DDS-1® ) n=113,107
      ITT,PP (placebo) n=109,106
05
Findings from studies

#

  • Diarrhea
  • Constipation
  • Bowel Habits
  • Global IBS Symptoms
  • Abdominal Pain / Discomfort
  • Bloating / Distention
  • Gas / Flatulence
  • Nausea / Vomiting
  • Mental Health
  • Quality of Life
  • Miscellaneous Symptoms
  • Notes

  • Study #1

    • Diarrhea

      • No subtype specific statistical analysis was conducted. At baseline, n=24 (21.6%) of participants in the DDS-1 group were classified as having diarrhea (a type 6 or 7 stool form on the bristol stool scale). By the end of treatment, n=7 (6.3%) of participants were classified as having constipation.

      • This was a 70.8% relative reduction in participants experiencing diarrhea from baseline till the end of treatment. This was a 49.8% relative therapeutic gain over the placebo group.

    • Constipation

      • No subtype specific statistical analysis was conducted. At baseline, n=24 (21.6%) of participants in the DDS-1 group were classified as having constipation (a type 1 or 2 stool form on the bristol stool scale). By the end of treatment, n=9 (8.1%) of participants were classified as having constipation.

      • This was a 62.5% relative reduction in participants experiencing constipation from baseline till the end of treatment. This was a 74.7% relative therapeutic gain over the placebo group, which experienced a higher occurrence of constipation by the end of treatment relative to baseline measurements.

    • Bowel Habits

      • Bowel habits were assessed via the IBS-SSS. The DDS-1 group experienced a mean absolute symptom score reduction of 22.89 points (36.3% mean relative reduction) that was statistically significant compared to placebo (p<0.001) by day 42 of the intervention.

      • The mean relative therapeutic gain over placebo was 23%. At baseline, the DDS-1 group had 43.2% (n=48/111) of participants experiencing abnormal stool form (stool types 1,2, 6, and 7 on a bristol stool scale).

      • By the end of treatment at day 42, 83.8% (n=93/109) of participants in the DDS-1 group were experiencing a normal stool form, while only 14.4% (n-16/109) had an abnormal stool form. This amounted to a 47.5% relative increase in individuals experiencing normal stool forms from baseline, and a 66.7% reduction in individuals experiencing abnormal stool forms from baseline.

      • The relative therapeutic gain over placebo for a reduction in participants experiencing abnormal stool form was 67.0%. Changes in bowel habits in the DDS-1 vs. placebo groups were statistically significant (p=0.002).For further details about bowel habit changes, see information in the constipation and diarrhea symptom columns. There were no statistically significant changes in the DDS-1 group for stool frequency.

      • For further details about bowel habit changes, see information in the constipation and diarrhea symptom columns. There were no statistically significant changes in the DDS-1 group for stool frequency.

    • Global IBS Symptoms

      • The DDS-1 group had baseline mean IBS-SSS scores of 310.90, which improved by a 133.4 point reduction, exceeding the MCID for this validated measurement tool. This effect was statistically significant compared to placebo by day 42 (p<0.001). The mean relative decrease in IBS-SSS total score was 42.9%. Relative mean therapeutic gain over placebo was 14.1%.

    • Abdominal Pain / Discomfort

      • Based on abdominal pain severity scores from the APS-NRS, the L. acidophilus DDS-1 group had 52.3% of participants classified as abdominal pain responders, meaning they had a >30% reduction in abdominal pain severity.

      • Analyses from day 21 and day 42 showed statistically significant improvements in abdominal pain severity scores for the DDS-1® group compared to the placebo and the other studied probiotic (UABla-12) groups.

      • The therapeutic gain over placebo for the DDS-1 group was 36.7% by day 42 (p<0.001). Results from another screening tool used in the study called the IBS symptom severity score (IBS-SSS) also revealed significant benefits for abdominal pain severity and duration compared to the placebo group and the UABla-12 probiotic group.

      • For the abdominal pain severity parameter, there was a mean absolute reduction of 32.94 points (-48.27%) from baseline by day 42. This was statistically significant compared to placebo (p<0.001) and the DDS-1 group had a mean therapeutic gain over placebo of 28.2%.

      • For abdominal pain duration, the DDS-1 group had an absolute mean reduction of 28.44 points (47.61%) by day 42 that was statistically significant compared to placebo (p<0.001). The mean therapeutic gain over placebo in the DDS-1 group was 32.3%.

    • Bloating / Distention

      • No data

    • Gas / Flatulence

      • No data

    • Nausea / Vomiting

      • No data

    • Mental Health

      • No data

    • Quality of Life

      • Baseline IBS-QOL mean scores in the DDS-1 group were 68.21. By day 42 mean scores were reduced to 53.94. This 14.27 point reduction meets the 14 point MCID threshold for the IBS-QOL tool.

      • The results in the DDS-1 group were significant on day 42 of the intervention (p=0.016). The relative mean therapeutic gain over placebo for the DDS-1 group was an 11.1% improvement in IBS-QOL scores. No significant differences were noted for the DDS-1 group for the perceived stress scale (PSS) negative factors, or PSS positive factors for the day 21 and day 42 measurement.

      • There was a statistically significant improvement for the PSS total score in the DDS-1 group compared to placebo (p0.023) at the day 42 measurement. The relative mean symptom score improvement was 18%, which was a 9.3% therapeutic gain over placebo.

      • For QOL measured on the IBS-SSS, the DDS-1 group experienced a mean relative improvement in symptom scores of 36.6% by day 42. The mean relative therapeutic gain over placebo was 18.7%

    • Miscellaneous Symptoms

      • No data

    • Notes

      • No data